BACKGROUND:Human immunodeficiency virus (HIV)-1 infected adults with low CD4 cell count have a higher risk of malaria infection and clinical malaria. We assessed the influence that HIV-1 immune suppression has on the efficacy of antimalarial treatment in adults with uncomplicated malaria. METHODS: This clinical trial included 971 Zambian adults with uncomplicated malaria. Patients were tested for HIV-1, and, if positive, a CD4 cell count was assessed. The primary outcome was recurrent parasitemia corrected by molecular genotyping within 45 days after treatment. RESULTS:HIV-1 infection was detected in 33% (320/971) of adult patients with malaria. Treatment failure was not associated with HIV-1 infection (relative risk [RR], 1.12 [95% confidence interval {CI}, 0.82-1.53]; P=.45). HIV-1-infected patients with a CD4 cell count <300 cells/microL had an increased risk of recurrent parasitemia, compared with those with a CD4 cell count >or=300 cells/microL (RR, 2.24 [95% CI, 1.20-4.14]; P=.01). After genotyping, the risk of recrudescence was higher in HIV-1-infected patients with a CD4 cell count <300 cells/microL than in the other patients with malaria (RR, 1.67 [95% CI, 1.13-2.47]; P=.02). CONCLUSION:HIV-1-infected patients with malaria with a CD4 cell count <300 cells/microL have a higher risk of experiencing a recrudescent infection, compared with those with a CD4 cell count >or=300 cells/microL or without HIV-1 infection. Trial registered at http://www.clinicaltrials.gov/; reference number NCT00304980.
RCT Entities:
BACKGROUND: Human immunodeficiency virus (HIV)-1 infected adults with low CD4 cell count have a higher risk of malaria infection and clinical malaria. We assessed the influence that HIV-1 immune suppression has on the efficacy of antimalarial treatment in adults with uncomplicated malaria. METHODS: This clinical trial included 971 Zambian adults with uncomplicated malaria. Patients were tested for HIV-1, and, if positive, a CD4 cell count was assessed. The primary outcome was recurrent parasitemia corrected by molecular genotyping within 45 days after treatment. RESULTS:HIV-1 infection was detected in 33% (320/971) of adult patients with malaria. Treatment failure was not associated with HIV-1 infection (relative risk [RR], 1.12 [95% confidence interval {CI}, 0.82-1.53]; P=.45). HIV-1-infectedpatients with a CD4 cell count <300 cells/microL had an increased risk of recurrent parasitemia, compared with those with a CD4 cell count >or=300 cells/microL (RR, 2.24 [95% CI, 1.20-4.14]; P=.01). After genotyping, the risk of recrudescence was higher in HIV-1-infectedpatients with a CD4 cell count <300 cells/microL than in the other patients with malaria (RR, 1.67 [95% CI, 1.13-2.47]; P=.02). CONCLUSION:HIV-1-infectedpatients with malaria with a CD4 cell count <300 cells/microL have a higher risk of experiencing a recrudescent infection, compared with those with a CD4 cell count >or=300 cells/microL or without HIV-1 infection. Trial registered at http://www.clinicaltrials.gov/; reference number NCT00304980.
Authors: Obinna N Nnedu; Grace C John-Stewart; Benson O Singa; Ben Piper; Phelgona A Otieno; Alicia Guidry; Barbra A Richardson; Judd Walson Journal: AIDS Care Date: 2012-04-26
Authors: Edwin Ochong; David J Bell; David J Johnson; Umberto D'Alessandro; Modest Mulenga; Sant Muangnoicharoen; Jean-Pierre Van Geertruyden; Peter A Winstanley; Patrick G Bray; Stephen A Ward; Andrew Owen Journal: Antimicrob Agents Chemother Date: 2008-08-25 Impact factor: 5.191
Authors: Abel Kakuru; Jane Achan; Mary K Muhindo; Gloria Ikilezi; Emmanuel Arinaitwe; Florence Mwangwa; Theodore Ruel; Tamara D Clark; Edwin Charlebois; Philip J Rosenthal; Diane Havlir; Moses R Kamya; Jordan W Tappero; Grant Dorsey Journal: Clin Infect Dis Date: 2014-04-23 Impact factor: 9.079
Authors: Samuel Malamba; Taylor Sandison; John Lule; Arthur Reingold; Jordan Walker; Grant Dorsey; Jonathan Mermin Journal: Am J Trop Med Hyg Date: 2010-05 Impact factor: 2.345